Empagliflozinum

Empagliflozinum est antidiabeticum et medicamentum ad therapiam diabetis melliti, modo typi 2, praescriptum^[1]. Licet, ut una cum metformino vel insulino praescribatur. Non commendatur Empagliflozinum therapiae diabetis melliti typi 1.

Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt.

Empagliflozinum
Cognitores
ChemSpider	10123957
PubChem	11949646
DrugBank	DB09038
Natura chemica

Formula summarum	C ₂₃H ₂₇ClO ₇
Massa molaris	450.91 g/mol
Natura pharmacologica
Codices ATC	A10BK03 (WHO) A10BD19 (WHO) A10BD20 (WHO)
Ad usum therapeuticum
Applicatio	per os
MedlinePlus	a614043 (Anglice)

Ut nomen indicat, Empagliflozinum gliflozinum est. Ergo substantia in renibus absorptionem glucosi inhibet. Vocatur quoque inhibitor SGLT2, quia per SGLT-2, proteinum 2 transportatoris natrii glucosique agit.

Nexus externi

Monographia apud drugs.com de Empagliflozino. (Anglice)

Notae

↑ Davies M. J., D'Alessio D. A., Fradkin J., Kernan W. N., Mathieu C., Mingrone G., Rossing P., Tsapas A., Wexler D. J., Buse J. B. (Dec 2018). "Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)". Diabetologia 61 (12): 2461-98

stipula

Haec stipula ad medicinam spectat. Amplifica, si potes!

[1] Davies M. J., D'Alessio D. A., Fradkin J., Kernan W. N., Mathieu C., Mingrone G., Rossing P., Tsapas A., Wexler D. J., Buse J. B. (Dec 2018). "Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)". Diabetologia 61 (12): 2461-98

[1]